Aim: To investigate changes in body weight trajectories after the addition of individual sulphonylureas (SUs) to metformin in patients with type 2 diabetes.
| INTRODUCTION
Avoiding relevant increases in body weight, particularly after starting new glucose-lowering agents, is an important treatment target in type 2 diabetes. 1 Weight increase in patients with type 2 diabetes is problematic because it contributes to increased insulin resistance and disease progression. [1] [2] [3] In trials investigating new glucose-lowering agents, body weight is used as a separate endpoint. Except for lifestyle factors, the various glucose-lowering agents have been reported to have either decreasing, neutral or increasing effects on body weight. Among the available agents, metformin is reported to have no effect on weight, [4] [5] [6] while several other glucose-lowering agents have been reported to cause small increases in weight. [7] [8] [9] [10] [11] [12] The UK Prospective Diabetes Study reported an increase in weight of~4 kg in the first 3 years after initiation of glibenclamide compared with metformin, after which weight remained relatively stable. 7 The A Diabetes Outcome Progression Trial (ADOPT) reported that glibenclamide monotherapy caused a 1.6-kg increase in weight in the first year compared with baseline, but remained stable after that for the next 5 years. 13 The magnitude of weight changes in daily practice after starting 15 It is unclear whether this weight increase is a class effect or should be attributed to specific SU drugs. As a consequence, there is a growing interest in within-class SU differences. Of the SUs available, gliclazide has a remarkable safety profile: its use is associated with exceptionally few hypoglycaemic events. 16 Furthermore, gliclazide can even be used in patients with renal impairment without dose adjustment 17, 18 and is possibly beneficial with respect to cardiovascular outcomes compared with other SUs. 19 Together, this led to the incorporation of gliclazide as the preferred SU in the Dutch 2013 diabetes guidelines when treatment intensification after metformin is required. 20 Evidence for within-class differences in weight change after the start of individual SUs could have consequences regarding the preferred agent when treatment intensification is needed. The aim of the present study was to investigate within-and between SUgroup weight trajectories, in a prospective primary care cohort of patients with type 2 diabetes, after starting add-on therapy with individual SUs, in addition to metformin.
| METHODS
The present study is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations. 21 
| Study design and data collection
The present study (part of Clinicaltrials.gov #NCT02133118) was an analysis of patients included in the prospective Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study. 22 The ZODIAC study started in 1998 and included patients diagnosed with type 2 diabetes who were treated exclusively in primary care. Since then, the ZODIAC study has expanded to more than 600 general practices in the north-eastern and western part of the Netherlands.
In the Netherlands, all inhabitants have a general practitioner and >80% of patients with type 2 diabetes are treated exclusively in primary care. 23 As part of the ZODIAC study, the following data are collected by general practitioners and sent to the diabetes centre annually: pres- 
| Outcome measures
The primary outcome of the study was mean yearly change in body weight compared with weight at baseline for each add-on group separately for 5 years. Secondary outcome was mean change in HbA1c compared with baseline. 
| Statistical analysis

| Ethics
In the ZODIAC study, patients consented to anonymous use of their data for study purposes. The medical ethics committee of Isala, Zwolle, the Netherlands approved the ZODIAC study (METC reference numbers 03.0316 and 07.0335).
| Patient involvement
Patients were not involved in the design of the study, the development of outcome measures or in the recruitment of patients.
| RESULTS
From the total number of metformin monotherapy users at the start of the study (n = 29 195), 2958 patients (10.1%) were included in the analysis. The number of patients at each selection stage is shown in Figure S1 , Supporting Information. Baseline characteristics are shown in 
| Weight changes during follow-up
The overall results of the linear mixed model analysis showed a nonsignificant (p = 0.24) linear change in weight during the follow-up period and a non-significant (p = 0.26) difference in weight between the add-on therapy combinations. In addition, the change in weight did not significantly differ between the add-on therapy combinations (p value for interaction = 0.67). The regression parameters of the fixed effects of the mixed model analysis are shown in Table S1 , Supporting Information. Estimated weights for the different add-on therapy combinations at yearly time points are shown in Table 2 and Figure 1A . After 5 years, a non-significant increase in weight was observed in the gliclazide and glibenclamide groups; in the glimepiride group no change was observed.
| Glucose control
The HbA1c results showed a non-linear trend over time. A quadratic trend was introduced in the mixed model analysis for the changes in HbA1c during follow-up. The results showed a significant overall quadratic trend (p < 0.005) in the HbA1c value during follow-up.
There was no significant (p = 0.37) difference between the different add-on therapy combinations, and a non-significant interaction effect (p = 0.14). In Table S2 , Supporting Information the regression parameters of the fixed effects of the mixed model analysis are presented.
Estimated HbA1c values for the different add-on therapy combinations at different time periods are shown in Table 3 and Figure 1B . In the gliclazide, glimepiride and tolbutamide add-on groups, the average HbA1c levels steadily decreased from 7.1% (54 mmol/mol) and remained below 7.0% (53 mmol/mol) during the first 4 years after intensification, and rose above 7.0% (53 mmol/mol) in the fifth year.
| DISCUSSION
In the present study, there was no evidence of a significant weight change within and between the four SU add-on groups in the years after starting an SU. When used as add-on therapy to metformin, increases in weight with similar glycaemic efficacy have been 31 Most studies showed only modest increases in body weight (ranging from 0.5 to 3 kg) and most had a maximum follow-up time of 12 months.
One study with 10 years of follow-up, showed that weight was gained only in the first 3 years after initiation of an SU. 26 The present results contrast with results from randomized controlled trials (RCTs). The differences in weight change between this study and previous RCTs could partly have resulted from differences in design and baseline factors. Compared with RCTs, the patients included in the present study differed with respect to glycaemic control; the average baseline HbA1c level in most RCTs [ranging from 7.3% (56 mmol/mol) to 8.5% (69 mmol/mol)] was higher than the These results indicate that it is possible to maintain strict glycaemic control in the majority of patients in a real-life setting without eral population studies performed in middle-and high-income countries and therefore is not necessarily related to diabetes medication. 35, 36 In the Netherlands, a form of protocol-based care is deployed, which probably could be an explanation for the on average small and seemingly non-relevant decrease in HbA1c. At the time the study was performed, patients treated in the Netherlands were checked at least once a year by their general practitioner and three times a year by practice nurses. During these visits there is a strong focus on lifestyle advice as well as glycaemic control. 20 When patients' HbA1c levels are above target, treatment is immediately intensified, even when they are only slightly above target. In the RCTs no structured lifestyle advice was described in the methods sections. Nonadherence to lifestyle advice has been associated with worsening glycaemic control and weight gain, [37] [38] [39] with subsequent increases in HbA1c leading to treatment intensification. 40 The sample used in the present study has a high degree of generalizability and represents the majority of primary care-treated patients in the Netherlands. Large regions of the Netherlands are participating in projects similar to that included the present study, and all patients with type 2 diabetes have the opportunity to opt out. In the Netherlands all patients have a primary care physician and >80% of all patients with type 2 diabetes are treated exclusively in primary care. 23 In contrast to the observational design of the present study, RCTs often have strict selection criteria, limiting the number of patients eligible for inclusion and possibly leading to sample selection bias and therefore complicating the generalizability to daily practice. 41 Strengths of the present study include the number of patients, the daily care setting and the new-user design, thereby avoiding two potential types of bias: underascertainment of weight changes that occur early after the start of add-on therapy and the inability to control for disease risk factors that may be altered by the study drugs themselves. 24 Furthermore, >97% of all observations on weight and 99% of all observations on HbA1c from any study visit were com- The study also has some important limitations. Although there were no significant within-class differences in weight change after starting SUs in the first 5 years after treatment intensification, the number of patients in the gliclazide and glibenclamide group was small and a potentially relevant increase in weight could not be excluded. Furthermore, the decrease in number of patients in the tolbutamide and glibenclamide groups was relatively high compared with the other groups. Secondly, baseline macrovascular complications differed between the SU groups. Although the Dutch diabetes guidelines do not base the choice of an oral glucose-lowering agent on the presence of macrovascular complications, this theoretically could have influenced the choice of SU; however, the post hoc sensitivity analysis (Tables S3 and S4 , Supporting Information) showed that the addition of macrovascular complications did not relevantly change the results.
Third, the quality and reliability of our data were dependent on the accuracy of the data provided by practice nurses and general practi- Furthermore, it is possible that patients who started to gain weight while using an SU wanted to try a different drug; however, we have no evidence that this is the case (Table S6 , Supporting Information).
The rapid decrease in number of patients after year 2 could complicate the interpretation of the results, but in the present study the CIs remain narrow. A common side effect of SUs as a group is severe hypoglycaemic events, which were not recorded in our database;
however, the hazard of severe hypoglycaemia is very limited in gliclazide users, 16 the most prescribed SU in the Netherlands.
Furthermore, as no significant differences in weight were found, a dose-response analysis was not performed.
In conclusion, there was no evidence of relevant within-class SU 
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